SK65598A3 - Antiglucocorticoid drug - Google Patents

Antiglucocorticoid drug Download PDF

Info

Publication number: SK65598A3
Authority: SK; Slovakia
Prior art keywords: pheromones; glucocorticoid; carbon atoms; aliphatic; chain length
Prior art date: 1996-01-31

Application number

SK655-98A

Other languages

English (en)

Slovak (sk)

Inventor

Sergei Dmitrievich Burlakov

Dmitry Dmitrievich Genkin

Kirill Gennadievich Surkov

Viktor Veniaminovich Tets

Original Assignee

Sergei Dmitrievich Burlakov

Dmitry Dmitrievich Genkin

Kirill Gennadievich Surkov

Viktor Veniaminovich Tets

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-31

Filing date

1996-02-01

Publication date

1998-09-09

1996-02-01 Application filed by Sergei Dmitrievich Burlakov, Dmitry Dmitrievich Genkin, Kirill Gennadievich Surkov, Viktor Veniaminovich Tets filed Critical Sergei Dmitrievich Burlakov

1998-09-09 Publication of SK65598A3 publication Critical patent/SK65598A3/sk

Links

239000003635 glucocorticoid antagonist Substances 0.000 title 1
239000003016 pheromone Substances 0.000 claims abstract description 35
239000003862 glucocorticoid Substances 0.000 claims abstract description 29
241000238631 Hexapoda Species 0.000 claims abstract description 10
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 9
150000002148 esters Chemical class 0.000 claims abstract description 5
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims abstract description 4
125000001931 aliphatic group Chemical group 0.000 claims abstract description 3
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims abstract 2
239000000203 mixture Substances 0.000 claims description 21
239000003795 chemical substances by application Substances 0.000 claims description 10
230000003637 steroidlike Effects 0.000 claims description 7
230000000694 effects Effects 0.000 abstract description 19
239000003814 drug Substances 0.000 abstract description 14
238000002360 preparation method Methods 0.000 abstract description 8
229940079593 drug Drugs 0.000 abstract description 7
230000002209 hydrophobic effect Effects 0.000 abstract description 5
230000001225 therapeutic effect Effects 0.000 abstract description 5
229940088597 hormone Drugs 0.000 abstract description 4
239000005556 hormone Substances 0.000 abstract description 4
238000002474 experimental method Methods 0.000 abstract description 2
230000035945 sensitivity Effects 0.000 abstract description 2
210000004962 mammalian cell Anatomy 0.000 abstract 2
230000033228 biological regulation Effects 0.000 abstract 1
230000000052 comparative effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
231100000053 low toxicity Toxicity 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 17
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 17
150000003431 steroids Chemical class 0.000 description 16
229960003248 mifepristone Drugs 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
239000008194 pharmaceutical composition Substances 0.000 description 8
-1 steroid compounds Chemical class 0.000 description 8
239000000126 substance Substances 0.000 description 8
230000002800 anti-glucocorticoid effect Effects 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
102000003676 Glucocorticoid Receptors Human genes 0.000 description 6
108090000079 Glucocorticoid Receptors Proteins 0.000 description 6
238000007918 intramuscular administration Methods 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
241000700605 Viruses Species 0.000 description 5
230000003388 anti-hormonal effect Effects 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000007689 inspection Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
239000012528 membrane Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
229960002537 betamethasone Drugs 0.000 description 4
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000000392 somatic effect Effects 0.000 description 4
239000003270 steroid hormone Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
229940037128 systemic glucocorticoids Drugs 0.000 description 4
241001465754 Metazoa Species 0.000 description 3
108010085012 Steroid Receptors Proteins 0.000 description 3
238000011161 development Methods 0.000 description 3
108091008039 hormone receptors Proteins 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000002502 liposome Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
239000002395 mineralocorticoid Substances 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000035515 penetration Effects 0.000 description 3
229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 3
230000008569 process Effects 0.000 description 3
102000005969 steroid hormone receptors Human genes 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
239000000006 Nitroglycerin Substances 0.000 description 2
206010040799 Skin atrophy Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
230000003160 anti-catabolic effect Effects 0.000 description 2
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
229960005084 calcitriol Drugs 0.000 description 2
230000001925 catabolic effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
229960001380 cimetidine Drugs 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
239000003163 gonadal steroid hormone Substances 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000013589 supplement Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000009182 swimming Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
MKBVGNJXUNEBAL-UHFFFAOYSA-N Amphenone B Chemical compound C=1C=C(N)C=CC=1C(C)(C(=O)C)C1=CC=C(N)C=C1 MKBVGNJXUNEBAL-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
QDVJHWWRLGOLNK-UHFFFAOYSA-N C(C)OC=1C=C(C=C2NCCC3=CC(=C(C=C23)OCC)OCC)C=CC1OCC.C1=NC=CC2=CC=CC=C12 Chemical class C(C)OC=1C=C(C=C2NCCC3=CC(=C(C=C23)OCC)OCC)C=CC1OCC.C1=NC=CC2=CC=CC=C12 QDVJHWWRLGOLNK-UHFFFAOYSA-N 0.000 description 1
238000011735 C3H mouse Methods 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 description 1
108010011732 Steroid 21-Hydroxylase Proteins 0.000 description 1
102000014169 Steroid 21-Hydroxylase Human genes 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000708 anti-progestin effect Effects 0.000 description 1
229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
239000013059 antihormonal agent Substances 0.000 description 1
239000003418 antiprogestin Substances 0.000 description 1
229940054021 anxiolytics diphenylmethane derivative Drugs 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000012866 crystallographic experiment Methods 0.000 description 1
239000003145 cytotoxic factor Substances 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
208000002925 dental caries Diseases 0.000 description 1
239000000551 dentifrice Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000035876 healing Effects 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
231100000017 mucous membrane irritation Toxicity 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000005501 phase interface Effects 0.000 description 1
239000002497 pheromone derivative Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
229960001670 trilostane Drugs 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000012795 verification Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
238000011680 zucker rat Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Securing Of Glass Panes Or The Like (AREA)
Crystals, And After-Treatments Of Crystals (AREA)

SK655-98A 1996-01-31 1996-02-01 Antiglucocorticoid drug SK65598A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
RU96101194/14A RU2125446C1 (ru)	1996-01-31	1996-01-31	Антиглюкокортикоидное лекарственное средство
PCT/RU1996/000028 WO1997027845A1 (en)	1996-01-31	1996-02-01	Antiglucocorticoid drug

Publications (1)

Publication Number	Publication Date
SK65598A3 true SK65598A3 (en)	1998-09-09

Family

ID=20175968

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK655-98A SK65598A3 (en)	1996-01-31	1996-02-01	Antiglucocorticoid drug

Country Status (24)

Country	Link
US (1)	US5965623A (lt)
EP (1)	EP0896819A4 (lt)
JP (1)	JPH11504946A (lt)
KR (1)	KR100347862B1 (lt)
CN (1)	CN1213964A (lt)
AU (1)	AU710479B2 (lt)
BG (1)	BG102709A (lt)
BR (1)	BR9612470A (lt)
CA (1)	CA2244985A1 (lt)
CZ (1)	CZ160598A3 (lt)
EE (1)	EE9800209A (lt)
GE (1)	GEP20001955B (lt)
HU (1)	HUP9900504A2 (lt)
LT (1)	LT4441B (lt)
LV (1)	LV12177B (lt)
MD (1)	MD1430B1 (lt)
MX (1)	MX9806182A (lt)
NO (1)	NO983508L (lt)
PL (1)	PL187564B1 (lt)
RU (1)	RU2125446C1 (lt)
SI (1)	SI9620053A (lt)
SK (1)	SK65598A3 (lt)
UA (1)	UA48212C2 (lt)
WO (1)	WO1997027845A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1929401A (en) *	1999-12-01	2001-06-12	Alydar Pharmaceuticals Ltd.	Method for screening non-peptide, non-steroid inverterbrate pheromones, compositions containing the same and use of the compositions to treat diseases, conditions, and symptoms thereof
US6548706B2 (en) *	1999-12-23	2003-04-15	Aerojet Fine Chemicals Llc	Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
US6806293B1 (en)	2001-03-12	2004-10-19	Darley Pharmaceuticals Ltd	Use of pheromone compounds having MAP kinase modulating activity
AU2001243556A1 (en) *	2001-03-12	2002-09-24	Alydar Pharmaceuticals, Inc.	Screening non-peptide, non-steroid invertebrate pheromone compounds for mitogen-activated protein kinase modulating activity
RU2211213C2 (ru) *	2001-05-16	2003-08-27	Закрытое Акционерное Общество "Асгл - Исследовательские Лаборатории"	Лекарственное средство, обладающее противоязвенным, кардиопротективным и противошоковым действием
US20040018959A1 (en) *	2002-05-02	2004-01-29	Randall S. Hickle	System and methods of lipid removal from the body
RU2222326C1 (ru) *	2002-10-09	2004-01-27	Российский онкологический научный центр им. Н.Н.Блохина РАМН	Способ лечения саркомы юинга
US6752649B2 (en) *	2002-11-07	2004-06-22	Xentris, Llc	Illuminated indicia power supply apparatus and method of manufacture
DE10335845B4 (de) *	2003-05-09	2006-08-31	Müller, Martina, Dr.med.	Pheromone als Antikrebsmittel
KR100556335B1 (ko) *	2004-02-05	2006-03-03	정만길	6알-(3,6-디데옥시-엘-아라비노-헥소피라노실옥시)헵타노익산, 그 제조방법 및 그를 포함하는 장기휴면 유발효과
WO2010017177A1 (en) *	2008-08-06	2010-02-11	The Trustees Of The University Of Pennsylvania	Ultrasonically induced release from polymer vesicles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US161926A (en)		1875-04-13		Improvement in ink-wells
US2900756A (en) *	1958-12-09	1959-08-25	Jacobson Martin	Attractants for the gypsy moth
EP0149847A3 (en) *	1983-12-26	1989-11-08	Eisai Co., Ltd.	Therapeutic and preventive agent containing dolichol
JPH0759504B2 (ja) *	1986-01-23	1995-06-28	エーザイ株式会社	ポリプレニルアルコ−ル含有注射剤
US5019569A (en) *	1986-11-03	1991-05-28	Ortho Pharmaceutical Corporation	Reversal of glucocorticoid-induced skin atrophy
US4740627A (en) *	1987-05-21	1988-04-26	Phillips Petroleum Company	Synthesis of E,Z-11-tetradecen-1-al
ATE80313T1 (de)	1988-02-29	1992-09-15	Pfizer	Mittel zur erhoehung des transdermalen penetrationsflusses.
US5190978A (en) *	1989-09-29	1993-03-02	Dai-Ichi Kogyo Seiyaku Co. Ltd.	Carcinostatic compositions and methods
FR2718354B1 (fr) *	1994-04-08	1996-05-03	Roussel Uclaf	Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.

1996
- 1996-01-02 UA UA98074187A patent/UA48212C2/uk unknown
- 1996-01-31 RU RU96101194/14A patent/RU2125446C1/ru not_active IP Right Cessation
- 1996-02-01 CN CN96180161A patent/CN1213964A/zh active Pending
- 1996-02-01 JP JP9527525A patent/JPH11504946A/ja active Pending
- 1996-02-01 EP EP96902026A patent/EP0896819A4/en not_active Withdrawn
- 1996-02-01 SK SK655-98A patent/SK65598A3/sk unknown
- 1996-02-01 AU AU46363/96A patent/AU710479B2/en not_active Ceased
- 1996-02-01 EE EE9800209A patent/EE9800209A/xx unknown
- 1996-02-01 GE GEAP19964288A patent/GEP20001955B/en unknown
- 1996-02-01 MD MD98-0171A patent/MD1430B1/ro unknown
- 1996-02-01 BR BR9612470A patent/BR9612470A/pt not_active Application Discontinuation
- 1996-02-01 SI SI9620053A patent/SI9620053A/sl not_active IP Right Cessation
- 1996-02-01 WO PCT/RU1996/000028 patent/WO1997027845A1/ru not_active Ceased
- 1996-02-01 HU HU9900504A patent/HUP9900504A2/hu unknown
- 1996-02-01 PL PL96322596A patent/PL187564B1/pl unknown
- 1996-02-01 CA CA002244985A patent/CA2244985A1/en not_active Abandoned
- 1996-02-01 US US08/930,733 patent/US5965623A/en not_active Expired - Fee Related
- 1996-02-01 KR KR10-1998-0705074A patent/KR100347862B1/ko not_active Expired - Fee Related
- 1996-02-01 CZ CZ981605A patent/CZ160598A3/cs unknown
1998
- 1998-04-21 LT LT98-054A patent/LT4441B/lt not_active IP Right Cessation
- 1998-05-28 LV LVP-98-126A patent/LV12177B/lv unknown
- 1998-07-30 NO NO983508A patent/NO983508L/no unknown
- 1998-07-31 MX MX9806182A patent/MX9806182A/es unknown
- 1998-08-20 BG BG102709A patent/BG102709A/xx unknown

Also Published As

Publication number	Publication date
RU2125446C1 (ru)	1999-01-27
HUP9900504A2 (en)	1999-09-28
EE9800209A (et)	1998-12-15
AU4636396A (en)	1997-08-22
WO1997027845A1 (en)	1997-08-07
NO983508D0 (no)	1998-07-30
KR19990076946A (ko)	1999-10-25
LV12177A (lv)	1998-12-20
LV12177B (lv)	1999-06-20
EP0896819A1 (en)	1999-02-17
MX9806182A (es)	1998-10-31
LT98054A (lt)	1998-10-26
CZ160598A3 (cs)	1998-08-12
LT4441B (lt)	1999-01-25
CN1213964A (zh)	1999-04-14
PL187564B1 (pl)	2004-08-31
EP0896819A4 (en)	2001-11-07
UA48212C2 (uk)	2002-08-15
CA2244985A1 (en)	1997-08-07
GEP20001955B (en)	2000-03-05
JPH11504946A (ja)	1999-05-11
SI9620053A (sl)	1998-04-30
PL322596A1 (en)	1998-02-02
AU710479B2 (en)	1999-09-23
US5965623A (en)	1999-10-12
BG102709A (bg)	1999-06-30
KR100347862B1 (ko)	2003-01-24
MD1430B1 (ro)	2000-03-31
NO983508L (no)	1998-07-30
BR9612470A (pt)	1999-07-13

Publication	Publication Date	Title
DE69735949T2 (de)	2007-01-04	Zusammensetzung geeignet zur behandlung der pferdelahmheit
JPS5823619A (ja)	1983-02-12	リウマチ様関節炎の治療薬
JPH0478616B2 (lt)	1992-12-11
US6306383B1 (en)	2001-10-23	Method for topical treatment of scars with protein kinase C inhibitors
JPH08502294A (ja)	1996-03-12	ニューモシスティス−カリニ肺炎の治療方法とそのために有用な化合物
SK65598A3 (en)	1998-09-09	Antiglucocorticoid drug
AU2010335656B2 (en)	2015-05-07	Pharmaceutical composition comprising solvent mixture and a vitamin D derivative or analogue
JP6931042B2 (ja)	2021-09-01	甲状腺ベータアゴニストの使用
JPS6041656A (ja)	1985-03-05	新規アミノ酸誘導体の製法
US6068860A (en)	2000-05-30	Pharmaceutical formulation
JPH0640914A (ja)	1994-02-15	フィソスチグミンの新誘導体、それらの用途及びそれらを含む製薬組成物
US20030199476A1 (en)	2003-10-23	Medicament for the stimulation of leucopoiesis and treatment of tumour and protozoan diseases acarinosis and arthropod-borne diseases and a method for production thereof
JP3793596B2 (ja)	2006-07-05	抗真菌性外用組成物
RU2225208C1 (ru)	2004-03-10	Фармацевтическая композиция, обладающая противовоспалительным и антиаллергическим действием
AU2001276254B2 (en)	2006-07-13	Liposomic formulation of clobetasol propionate
UA113283C2 (xx)	2017-01-10	19-норстероїди і їх застосування для лікування прогестеронзалежних станів
GB2068227A (en)	1981-08-12	Topical ointment
EP0106251A1 (en)	1984-04-25	Pyrazolidinedione derivative having vasodilating, antiaggregating and hypocholesterolemic activities
US5334385A (en)	1994-08-02	New alkaloid derivatives, their use and pharmaceutical formulations containing them
Dipasquale et al.	1970	Modified granuloma pouch procedure for the evaluation of topically applied anti-inflammatory steroids
WO2026084761A2 (en)	2026-04-23	Conformationally tunable lipid compositions and therapeutic uses thereof
Matyushin et al.	1995	A water-soluble form of estradiol with estrogenic and cardiotropic activity
JPS58206521A (ja)	1983-12-01	抗腫瘍剤
WO2002013791A2 (en)	2002-02-21	Steroid hormones as transfer agents